Henk Vrieselaar - stock.adobe.com Roche has signed a definitive merger agreement to acquire 89bio and its Phase III candidate pegozafermin, an FGF21 analogue for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis (MASH). The deal is expected to close in Q4 2025.
Tag Archive for: Roche
Marcus Krauss - stock.adobe.com Data on the primary endpoint of BioNTech’s/Duality Biologics’ pivotal Phase III study of its HER2 antibody-drug conjugate BNT323/DB-1303 are not yet public, However, BioNTech says that progression-free survival is better than with Roche’s second-line breast cancer therapy Kadcyla.
adobe stock photos - Sundry Photography The US Roche unit Genentech Inc has signed a US$400 million licence deal with British NativeMS specialist OMass Therapeutics Ltd. Under the exclusive collaboration and licence agreement, Genentech intends to commercialise therapies for inflammatory bowel disease.
Pilatus BiosciencesPilatus Biosciences AG, a Swiss biotechnology company headquartered in Epalinges with operations in the United States and South Korea, has entered into a clinical trial collaboration with Roche AG. As part of the agreement, Roche will provide its PD-L1 immune checkpoint inhibitor atezolizumab for use in a Phase I study evaluating the combination of atezolizumab with Pilatus’s investigational CD36 inhibitor, PLT012, in patients with hepatocellular carcinoma (HCC).
Centauri TherapeuticsImmunotherapy company Centauri Therapeutics Ltd, based in Alderley Park, Cheshire, UK, has announced the appointment of Dr Debra Barker as Chief Medical Officer (CMO).
MichaelVi - stock.adobe.comGerman researchers have identified a promising new target to stop the inflammatory response in ulcerative colitis—a breakthrough that could help prevent the progression to colorectal cancer. Phase II clinical trials of a corresponding monoclonal antibody, licensed by Roche, are expected to begin soon.
Adobe Stock - TechArtTrends For nearly two decades, Roche AG has been searching for a next-generation sequencing method in personalised medicine to overcome the limitations of short read lengths in existing sequencing technologies. Following beta testing, the company plans to launch its new Sequencing by Expansion (SBX) technology commercially next year.
adobe stock - peterschreiber.media Despite the World Trade Organisation’s (WTO) ban of tariffs on pharmaceuticals, US President Donald Trump has announced he would consider imposing tariffs on pharmaceutical products. In a fast reaction, Swiss pharmaceutical giants Roche and Novartis, which are heavily dependent on the US market, have announced upcoming investments in the US as a production location by 2030.
asobe stock photos - catalin Roche is extending its obesity pipeline signing a US$5.3bn biobucks deal with Zealand Pharma A/S, who will co-develop and co-commercialise a monotherapy of its long-acting amylin analogue petrelintide with the Swiss pharma giant in the US and Europe and do the same for a combo of petrelintide and Roche’s GLP1/GIP receptor agonist CTT388.
Roche AGRoche researchers have introduced a greatly improved long-read nanopore sequencing method that has the potential to erase the sequencing-by-synthesis approach of market leader Illumina.